Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,502.00
(
2.50%
)
US TECH 100
22,979.60
(
2.90%
)
Dow Jones
46,222.25
(
2.23%
)
Brent Oil
103.84
(
-4.36%
)
Bitcoin
67,767.50
(
1.60%
)
News Focus
News Focus
Post# of 257320
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122828
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 180658

Tuesday, 10/28/2014 7:57:30 PM

Tuesday, October 28, 2014 7:57:30 PM

Post# of 257320
GILD -4% AH on “light” 3Q14 results:

http://blogs.barrons.com/stockstowatchtoday/2014/10/28/gilead-sciences-earnings-miss-forecasts-as-aca-drives-higher-costs/

Gilead reported a profit of $1.84 a share not including special items, missing forecasts for $1.92 a share, on sales of $6.04 billion, topping estimates for $5.98 billion. …Affordable Care Act-related costs knocked 21 cents off of earnings.

3Q14 Sovaldi sales were $2.80B (vs $3.84B in 2Q14), of which ~$2.2B was from the US market. (The Harvoni launch occurred after the end of 3Q14.)

GILD’s PR:
http://finance.yahoo.com/news/gilead-sciences-announces-third-quarter-200500161.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today